Completed
OBSERVATIONAL
NCT05041348
Metabonomic of Patients With Hepatitis B Cirrhosis Complicated With Sarcopenia.
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Sarcopenia is a common complication in liver cirrhosis patients and has been confirmed that associated with poor prognosis. China has the world's largest burden of hepatitis B virus-related liver cirrhosis (HBV-related liver cirrhosis). However, the relationship between HBV-related liver cirrhosis patients with muscle mass loss and normal muscle mass is remain largely unknown. Our study aimed to reveal the metabolic profile and identify potential biomarkers of muscle mass loss in HBV-related liver cirrhosis.
Interventions
Name:
CT at the level of the third lumbar vertebra (L3)
Type:
DIAGNOSTIC_TEST
Description:
Muscle mass loss was defined as an skeletal muscle mass index (SMI) less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
Primary Outcomes
Measure:
amino acids metabolism
TimeFrame:
2021.09.01-2022.08.01
Description:
Arginine biosynthesis, Phenylalanine, tyrosine and tryptophan biosynthesis were the enrichment pathway in two groups.
Measure:
central carbon metabolism
TimeFrame:
2021.09.01-2022.08.01
Description:
D-fructose-6-phosphate,L-glutamic acid, and Fumaric acid were selected as differential metabolites in pathway of central carbon metabolism.
Trial Information
NCT ID
NCT05041348
Status
Completed
Study Type
OBSERVATIONAL
Sponsor
The Affiliated Hospital of Qingdao University
Last Updated
December 15, 2025